Robocath’s joint venture, Cathbot, concludes first clinical study in China to evaluate robotic PCI safety and efficacy - End of study brings Robocath closer to commercializing R-One in China in 2023 - 149 patients enrolled over six months in four Chinese centers - Results of first vascular robotics study on this scale in China will be published in March 2023 Rouen, France, July 20, 2022 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that its joint venture, Cathbot, established in 2020 with MicroPort through its robotic subsidiary MedBot,...